Edwards Lifesciences Corp
EW
View Detailed Chart
82.410USD
-1.070-1.28%
Close 10/31, 16:00（ET）Quotes delayed by 15 min
48.45BMarket Cap
11.68P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-1.28%
5 Days
+7.68%
1 Month
+5.97%
6 Months
+9.17%
Year to Date
+11.32%
1 Year
+20.08%
View Detailed Chart
TradingKey Stock Score of Edwards Lifesciences Corp
Currency: USD Updated: 2025-10-30Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Edwards Lifesciences Corp's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
35
analysts
Buy
Current Rating
88.635
Target Price
+7.19%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Edwards Lifesciences Corp Highlights
StrengthsRisks
Edwards Lifesciences Corporation is a global structural heart innovation company. The Company is engaged in patient-focused medical innovations for structural heart disease and invests in research and development to transform care for those impacted by structural heart disease. Its products are categorized into groups, including Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart (Surgical). It develops transcatheter heart valve replacement technologies designed for the minimally invasive replacement of aortic heart valves. The Edwards SAPIEN family of valves includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra, and the Edwards SAPIEN 3 Ultra RESILIA systems, are catheter-based approaches for treating severe symptomatic aortic stenosis. Its PASCAL PRECISION and Cardioband transcatheter valve repair systems are commercially available in Europe for mitral and tricuspid valve repair.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 5.44B.
Fairly Valued
The company’s latest PE is 11.98, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 518.54M shares, decreasing 6.03% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 3.04M shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Edwards Lifesciences Corp Info
Edwards Lifesciences Corporation is a global structural heart innovation company. The Company is engaged in patient-focused medical innovations for structural heart disease and invests in research and development to transform care for those impacted by structural heart disease. Its products are categorized into groups, including Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart (Surgical). It develops transcatheter heart valve replacement technologies designed for the minimally invasive replacement of aortic heart valves. The Edwards SAPIEN family of valves includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra, and the Edwards SAPIEN 3 Ultra RESILIA systems, are catheter-based approaches for treating severe symptomatic aortic stenosis. Its PASCAL PRECISION and Cardioband transcatheter valve repair systems are commercially available in Europe for mitral and tricuspid valve repair.
Ticker SymbolEW
CompanyEdwards Lifesciences Corp
CEOMr. Bernard J. Zovighian
Websitehttps://www.edwards.com
Related Instruments
+2.00%
+0.85%
+0.15%
+0.14%
+2.20%
+2.08%
-2.12%
-0.07%
+0.17%
+1.96%
+24.80%
-0.01%
+2.88%
+1.75%
+7.01%
-3.19%
-0.07%
+1.92%
-2.20%
+0.60%Popular Symbols
